Kiniksa Pharmaceuticals (KNSA) News Today → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free KNSA Stock Alerts $19.22 +0.16 (+0.84%) (As of 06/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 2:30 AM | americanbankingnews.comComparing Kiniksa Pharmaceuticals (NASDAQ:KNSA) & Inventiva (NASDAQ:IVA)June 9 at 11:55 AM | marketbeat.comRubric Capital Management LP Cuts Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Rubric Capital Management LP lessened its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,907,501 shares of the company's stock after selling 169,948 sJune 4, 2024 | globenewswire.comKiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceMay 19, 2024 | marketbeat.comJump Financial LLC Makes New $951,000 Investment in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Jump Financial LLC bought a new position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 54,220 shares of the company's stockMay 10, 2024 | markets.businessinsider.comMarket Underestimates Kiniksa Pharmaceuticals’ Abiprubart Potential Despite Positive Industry IndicatorsMay 7, 2024 | globenewswire.comKiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care ConferenceMay 4, 2024 | msn.comWells Fargo Initiates Coverage of Kiniksa Pharmaceuticals (KNSA) with Overweight RecommendationMay 3, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Coverage Initiated at Wells Fargo & CompanyWells Fargo & Company assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday. They set an "overweight" rating and a $34.00 target price on the stock.May 1, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $30.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. increased their price target on Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the stock an "overweight" rating in a research report on Wednesday.April 26, 2024 | finance.yahoo.comAnalyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter ReportApril 25, 2024 | seekingalpha.comKiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call TranscriptApril 25, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Forecasted to Post Q2 2024 Earnings of ($0.06) Per ShareKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Stock analysts at Wedbush raised their Q2 2024 earnings per share estimates for Kiniksa Pharmaceuticals in a report released on Tuesday, April 23rd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per shApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug ProspectsApril 24, 2024 | markets.businessinsider.comCan Growing Adoption Of Arcalyst Drive KNSA Stock Up?April 24, 2024 | seekingalpha.comKiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take ShapeApril 24, 2024 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call TranscriptApril 24, 2024 | finance.yahoo.comKiniksa Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsApril 24, 2024 | marketbeat.comEvercore ISI Boosts Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target to $30.00Evercore ISI boosted their price objective on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an "outperform" rating in a report on Wednesday.April 24, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Announces Quarterly Earnings Results, Misses Estimates By $0.11 EPSKiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.11). Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative return on equity of 6.12%. The firm had revenue of $79.90 million for the quarter, compared to the consensus estimate of $76.97 million. During the same quarter last year, the company earned ($0.18) earnings per share. The firm's revenue was up 65.4% on a year-over-year basis.April 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial ExecutionApril 23, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Outperform Rating from WedbushWedbush reaffirmed an "outperform" rating and issued a $30.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday.April 23, 2024 | seekingalpha.comKiniksa Pharmaceuticals, Ltd. 2024 Q1 - Results - Earnings Call PresentationApril 23, 2024 | msn.comKiniksa Pharmaceuticals reports mixed Q1 results; raises FY24 outlookApril 23, 2024 | markets.businessinsider.comKNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024April 23, 2024 | finance.yahoo.comKiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue ForecastsApril 23, 2024 | globenewswire.comKiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio ExecutionApril 20, 2024 | investing.comKiniksa Pharmaceuticals Ltd (KNSA)April 17, 2024 | marketbeat.comKiniksa Pharmaceuticals (KNSA) Scheduled to Post Quarterly Earnings on TuesdayKiniksa Pharmaceuticals (NASDAQ:KNSA) will be releasing earnings before the market opens on Tuesday, April 23, Zacks reports.April 16, 2024 | globenewswire.comKiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024April 9, 2024 | marketbeat.comVanguard Group Inc. Sells 128,255 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Vanguard Group Inc. trimmed its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 4.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,958,957 shares of the company's stock after selling 128April 5, 2024 | marketbeat.comWedbush Research Analysts Reduce Earnings Estimates for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Investment analysts at Wedbush decreased their FY2024 earnings per share estimates for shares of Kiniksa Pharmaceuticals in a research note issued to investors on Tuesday, April 2nd. Wedbush analyst D. Nierengarten now expects that the cApril 4, 2024 | marketbeat.comFY2027 EPS Estimates for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Reduced by WedbushKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Investment analysts at Wedbush dropped their FY2027 earnings estimates for shares of Kiniksa Pharmaceuticals in a report released on Tuesday, April 2nd. Wedbush analyst D. Nierengarten now expects that the company will earn $0.15 per shaApril 3, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 3.6% Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 3.6%April 2, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Earns "Outperform" Rating from WedbushWedbush restated an "outperform" rating and issued a $30.00 price target (up previously from $28.00) on shares of Kiniksa Pharmaceuticals in a report on Tuesday.April 2, 2024 | globenewswire.comKiniksa Pharmaceuticals Announces Development Indication for AbiprubartMarch 16, 2024 | insidertrades.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sells 5,582 Shares of StockMarch 15, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Holdings Lowered by Hudson Bay Capital Management LPHudson Bay Capital Management LP trimmed its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 55.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 302,500 shares of the compaMarch 12, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by AQR Capital Management LLCAQR Capital Management LLC lowered its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 36.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 323,578 shares of the company's stock after selling 187March 7, 2024 | msn.com5 Biotech Stocks With 26% Upside Potential or MoreMarch 6, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Buys 134,070 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Schonfeld Strategic Advisors LLC increased its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 180.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 208,500 shares of the company's stock after purchasing an addMarch 4, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Hits New 12-Month High at $22.09Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 52-Week High at $22.09March 3, 2024 | investing.comEarnings call: Kiniksa Pharmaceuticals sees robust growth in ARCALYST salesMarch 3, 2024 | wsj.comKiniksa Pharmaceuticals Ltd.March 1, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna Sells 5,126 SharesKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CAO Michael R. Megna sold 5,126 shares of the firm's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares of the company's stock, valued at approximately $383,242.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 1, 2024 | seekingalpha.comKiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comKiniksa Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsMarch 1, 2024 | marketbeat.comQ1 2024 EPS Estimates for Kiniksa Pharmaceuticals, Ltd. Boosted by Analyst (NASDAQ:KNSA)Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Analysts at Wedbush lifted their Q1 2024 earnings estimates for shares of Kiniksa Pharmaceuticals in a research note issued on Wednesday, February 28th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings peMarch 1, 2024 | finance.yahoo.comChief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)February 29, 2024 | finance.yahoo.comAre You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great ChoiceFebruary 29, 2024 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Don’t make this retirement mistake (Ad)If you have over $100,000 in your 401K or IRA… Then listen closely… Your money is rotting away, and you might not even realize it. Reserve your seat here. KNSA Media Mentions By Week KNSA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNSA News Sentiment▼0.340.75▲Average Medical News Sentiment KNSA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNSA Articles This Week▼32▲KNSA Articles Average Week Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Akero Therapeutics News Supernus Pharmaceuticals News Arcutis Biotherapeutics News Innoviva News Ocular Therapeutix News Pliant Therapeutics News Theravance Biopharma News Organon & Co. News BridgeBio Pharma News Grifols News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNSA) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored